2. Search Result
Search Result
Results for "

Glucose uptake

" in MedChemExpress (MCE) Product Catalog:

87

Inhibitors & Agonists

1

Screening Libraries

3

Fluorescent Dye

1

Biochemical Assay Reagents

3

Peptides

26

Natural
Products

1

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N8490
    Eicosyl ferulate

    		Others Metabolic Disease
    Eicosyl ferulate, a phenolic compound, is isolated from the fresh root and stem of Aristolochia kankauensis. Eicosyl ferulate exhibits glucose uptake stimulatory activity .
    Eicosyl ferulate
  • HY-158302
    Glutor

    		GLUT Apoptosis Cancer
    Glutor is a selective GLUT 1/2/3 inhibitor that can suppress glucose uptake. Glutor can inhibit glycolysis and has anti-tumor activity, inducing cell apoptosis .
    Glutor
  • HY-N7605
    11-epi-mogroside V

    		Others Metabolic Disease
    11-epi-mogroside V is a mogroside in the fruit of Siraitia grosvenori. 11-epi-mogroside V exhibits considerable bioactivity in promoting glucose uptake in human HepG2 cells in vitro .
    11-epi-mogroside V
  • HY-113870
    6-NBDG

    		Fluorescent Dye Others
    6-NBDG is a fluorescent glucose analogue, it can be used for fluorescence imaging and monitoring glucose transport and uptake. 6-NBDG can be used as a fluorescent probe for detecting macrophage-rich atherosclerotic plaques .
    6-NBDG
  • HY-146036
    NADH-IN-1

    		Endogenous Metabolite Metabolic Disease
    NADH-IN-1 has NADH:ubiquinone oxidoreductase inhibitory activity with an IC50 value of 27 μM. NADH-IN-1 can effectively stimulate glucose uptake in vitro. NADH-IN-1 is readily metabolised by the liver. NADH-IN-1 can be used for researching diabetes .
    NADH-IN-1
  • HY-125062
    Steviolmonoside

    Glucosilsteviol

    		 GLUT Metabolic Disease
    Steviolmonoside (Glucosilsteviol) is a structural analogue of steviol. Steviolmonoside decreases glucose production and inhibits oxygen uptake in rat renal cortical tubules .
    Steviolmonoside
  • HY-W411439
    1-O-p-Coumaroyl-β-D-glucose

    		GLUT Metabolic Disease
    1-O-p-Coumaroyl-β-D-glucose can promote glucose uptake in HuH7 cells, and be be extracted from Luffa cylindrica (L.) Roem (sponge gourds) .
    1-O-p-Coumaroyl-β-D-glucose
  • HY-167857
    (Rac)-Glutipyran

    		GLUT Cancer
    (Rac)-Glutipyran is a broad-spectrum GLUT inhibitor that targets both GLUT1 and GLUT3. (Rac)-Glutipyran inhibits glucose uptake and suppresses the growth of multiple cancer cells, significantly inhibiting PANC-1 cell growth (IC50=1.8 μM) and glucose uptake (IC50=0.13 μM) .
    (Rac)-Glutipyran
  • HY-N1185
    Tagitinin A

    		Others Metabolic Disease
    Tagitinin A is a sesquiterpene with anti-hyperglycemic activity. Tagitinin A significantly inhibits glucose uptake in differentiated 3T3-L1 adipocytes .
    Tagitinin A
  • HY-139172
    MD001

    		PPAR Metabolic Disease
    MD001 is a PPARα/γ dual agonist and can increase the transcriptional activity of PPARα and PPARγ. MD001 enhances the expression of genes related to β-oxidation and fatty acid and glucose uptake .
    MD001
  • HY-N4095
    Brevifolincarboxylic acid

    		Aryl Hydrocarbon Receptor Glycosidase Reactive Oxygen Species GLUT Metabolic Disease Inflammation/Immunology Cancer
    Brevifolincarboxylic acid is a phenolic compound. Brevifolincarboxylic acid can be isolated from Duchesnea chrysantha. Brevifolincarboxylic acid inhibits α-glucosidase with an IC50 value of 323.46 μM. Brevifolincarboxylic acid has an inhibitory effect on the aryl hydrocarbon receptor (AhR). Brevifolincarbacid scavenges ROS. Brevifolincarbacid restores the glucose uptake activity of myotubes. Brevifolincarboxylic acid has antitumor activity against lung and gastric cancer. Brevifolincarbacid can be used in the study of diabetes and inflammatory diseases .
    Brevifolincarboxylic acid
  • HY-163294
    PPARγ agonist 10

    		PPAR Metabolic Disease
    PPARγ agonist 10 (compound 33g) is a PPARγ agonist, and stimulats the insulin secretion, glucose uptake and insulin Sensitivity in βTC6 Cells .
    PPARγ agonist 10
  • HY-18686
    AS1949490
    1 Publications Verification

    		 Phosphatase Akt Metabolic Disease
    AS1949490 is a potent, orally active, selective SHIP2 phosphatase inhibitor with IC50 values of 0.34, 0.62, 13, >50, >50, and >50 µM for Mouse SHIP2, Human SHIP2, Human SHIP1, Human PTEN, Human synaptojanin, and Human myotubularin, respectively. AS1949490 increases the phosphorylation of Akt, glucose consumption and glucose uptake. AS1949490 activates intracellular insulin signalling pathways. AS1949490 can be used for research of diabetes .
    AS1949490
  • HY-153018
    PTP1B-IN-22

    		Phosphatase Metabolic Disease
    PTP1B-IN-22, a ZINC02765569 derivative, is a potent protein tyrosine phosphatase 1B (PTP1B) inhibitor. PTP1B-IN-22 has PTP1B inhibition and glucose uptake in skeletal muscle L6 myotubes .
    PTP1B-IN-22
  • HY-142088
    Beauverolide Ka

    		Endogenous Metabolite Metabolic Disease
    Beauverolide Ka, a cyclotetradepsipeptide, is a metabolite of Beauveria bassiana fungus. Beauverolide Ka stimulates glucose uptake in cultured rat L6 myoblasts at 50 μM. Beauverolide Ka exhibits protecting effects on HEI-OC1 cells at 10 μM and shows dose-dependent activity in both L6 myoblasts and myotubes .
    Beauverolide Ka
  • HY-103721
    SIRT6-IN-2

    		Sirtuin Cancer
    SIRT6-IN-2 (Compound 5) is a selective SIRT6 inhibitor (IC50: 34 μM). SIRT6-IN-2 increases acetylation of H3K9 and increases glucose uptake in cultured cells. SIRT6-IN-2 also reduces T cell proliferation. SIRT6-IN-2 has immunosuppressive and chemosensitizing effects .
    SIRT6-IN-2
  • HY-N3426
    Kazinol B

    		NO Synthase Akt AMPK Metabolic Disease
    Kazinol B, a prenylated flavan with a dimethyl pyrane ring, is an inhibitor of nitric oxide (NO) production. Kazinol B improves insulin sensitivity by enhancing glucose uptake via the insulin-Akt signaling pathway and AMPK activation. Kazinol B has the potential for diabetes mellitus research .
    Kazinol B
  • HY-W040127
    Peonidin 3-O-glucoside chloride

    		Insulin Receptor Metabolic Disease
    Peonidin 3-O-glucoside chloride is an agonist of the free fatty acid receptor FFAR1 and Glucokinase. Peonidin 3-O-glucoside chloride enhances insulin secretion of pancreatic beta cells and increases glucose uptake by liver cells. Peonidin 3-O-glucoside chloride activates FFAR1, promotes the phosphorylation of related proteins in the insulin secretion pathway, and increases the expression of FFAR1. In liver cells, Peonidin 3-O-glucoside chloride activates GK and regulates proteins associated with carbohydrate metabolism. Peonidin 3-O-glucoside chloride can be used in diabetes research .
    Peonidin 3-O-glucoside chloride
  • HY-W176629
    Hydrocotarnine

    		E1/E2/E3 Enzyme Interleukin Related Neurological Disease Metabolic Disease Inflammation/Immunology
    Hydrocotarnine is a Cbl inhibitor, and results in inflammasome-mediated IL-18 secretion in colitis. Hydrocotarnine increases expression of GLUT1 and cellular glucose uptake in glycolytic metabolism. Hydrocotarnine acts as an agent that provides analgesic effect in cancer research .
    Hydrocotarnine
  • HY-N0457
    Chicoric acid
    1 Publications Verification

    Cichoric acid; Dicaffeoyltartaric acid

    		 Reactive Oxygen Species Apoptosis Metabolic Disease Inflammation/Immunology
    Chicoric acid (Cichoric acid), an orally active dicaffeyltartaric acid, induces reactive oxygen species (ROS) generation. Chicoric acid inhibits cell viability and induces mitochondria-dependent apoptosis in 3T3-L1 preadipocytes through ROS-mediated PI3K/Akt and MAPK signaling pathways. Chicoric acid increases glucose uptake, improves insulin resistance, and attenuates glucosamine-induced inflammation. Chicoric acid has antidiabetic properties and antioxidant, anti-inflammatory effects .
    Chicoric acid
  • HY-N0457R
    Chicoric acid (Standard)

    		Reactive Oxygen Species Apoptosis Metabolic Disease Inflammation/Immunology
    Chicoric acid (Standard) is the analytical standard of Chicoric acid. This product is intended for research and analytical applications. Chicoric acid (Cichoric acid), an orally active dicaffeyltartaric acid, induces reactive oxygen species (ROS) generation. Chicoric acid inhibits cell viability and induces mitochondria-dependent apoptosis in 3T3-L1 preadipocytes through ROS-mediated PI3K/Akt and MAPK signaling pathways. Chicoric acid increases glucose uptake, improves insulin resistance, and attenuates glucosamine-induced inflammation. Chicoric acid has antidiabetic properties and antioxidant, anti-inflammatory effects .
    Chicoric acid (Standard)
  • HY-N8438
    Methyl tetracosanoate

    Methyl lignocerate; Tetracosanoic Acid Methyl Ester

    		 Others Metabolic Disease
    Methyl tetracosanoate (Methyl lignocerate) is a fatty acid methyl ester with anti-diabetic activity .
    Methyl tetracosanoate
  • HY-N5083
    Saponarin
    1 Publications Verification

    		 PERK NF-κB p38 MAPK AMPK Interleukin Related COX Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    Saponarin is an orally active flavonoid compound. Saponarin can be isolated from Gypsophila trichotoma. Saponarin inhibits ERK/p38, NF-κB and MAPK phosphorylation and activates AMPK. Saponarin reduces IL-1β and COX-2. Saponarin has antioxidant, anti-inflammatory, hepatoprotective, hypoglycemic and hypotensive effects. Saponarin improves sleep disorders .
    Saponarin
  • HY-N5083R
    Saponarin (Standard)

    		Reference Standards PERK NF-κB p38 MAPK AMPK Interleukin Related COX Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    Saponarin (Standard) is the analytical standard of Saponarin (HY-N5083). This product is intended for research and analytical applications. Saponarin is an orally active flavonoid compound. Saponarin can be isolated from Gypsophila trichotoma. Saponarin inhibits ERK/p38, NF-κB and MAPK phosphorylation and activates AMPK. Saponarin reduces IL-1β and COX-2. Saponarin has antioxidant, anti-inflammatory, hepatoprotective, hypoglycemic and hypotensive effects. Saponarin improves sleep disorders .
    Saponarin (Standard)
  • HY-153612
    MMV009085

    		GLUT Parasite Infection Inflammation/Immunology
    MMV009085 is a potent PfHT1 (Plasmodium falciparum hexose transporter)-specific inhibitor and a potential anti-malarial agent . MMV009085 is also a human glucose transporter inhibitor, it has high potency in inhibiting both glucose uptake (IC50: 2.6 μM in glucose uptake assay) and growth of the parasites (EC50: 1.23±0.04 μM against 3D7) .
    MMV009085
  • HY-101903R
    BMS-309403 (Standard)

    		Reference Standards FABP Cardiovascular Disease Metabolic Disease
    BMS-309403 (Standard) is the analytical standard of BMS-309403. This product is intended for research and analytical applications. BMS-309403 is a potent, orally active and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells .
    BMS-309403 (Standard)
  • HY-101903A
    BMS-309403 sodium
    10+ Cited Publications

    		 FABP Cardiovascular Disease Metabolic Disease
    BMS-309403 sodium is a potent, orally active, and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor, with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 sodium interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 sodium improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells .
    BMS-309403 sodium
  • HY-101903
    BMS-309403
    10+ Cited Publications

    		 FABP Cardiovascular Disease Metabolic Disease
    BMS-309403 is a potent, orally active and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells .
    BMS-309403
  • HY-101903AR
    BMS-309403 sodium (Standard)

    		Reference Standards FABP Cardiovascular Disease Metabolic Disease
    BMS-309403 (sodium) (Standard) is the analytical standard of BMS-309403 (sodium). This product is intended for research and analytical applications. BMS-309403 sodium is a potent, orally active, and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor, with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 sodium interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 sodium improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells .
    BMS-309403 sodium (Standard)
  • HY-N7912
    Pterosin A

    (2S)-Pterosin A

    		 Others Metabolic Disease
    Pterosin A is an orally active anti-diabetic agent. Pterosin A promotes glucose uptake, increases serum insulin, and improves hyperglycemia and glucose intolerance in diabetic mice. Pterosin A can be isolated from Pteridium aquilinum .
    Pterosin A
  • HY-148940
    Docosahexaenoyl glycerol

    		Cannabinoid Receptor Inflammation/Immunology
    Docosahexaenoyl glycerol is an analog of endocannabinoid, which stimulates the glucose uptake and exhibits anti-inflammatory efficacy .
    Docosahexaenoyl glycerol
  • HY-N2486
    Desoxyrhaponticin
    1 Publications Verification

    		 Fatty Acid Synthase (FASN) Apoptosis Cancer
    Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects.
    Desoxyrhaponticin
  • HY-156690
    2-Quinizarincarboxylic acid

    		Others Metabolic Disease
    2-Quinizarincarboxylic acid (Compound 15) is a glucose uptake inhibitor, with the inhibitory rate of 24.9% at 50 μM .
    2-Quinizarincarboxylic acid
  • HY-124417
    SBI-477 analog

    		GLUT Metabolic Disease
    SBI-477 (compound 41) analog inhibits intracellular lipid accumulation, increase celluar glucose uptake .
    SBI-477 analog
  • HY-139409
    2-Deoxy-D-glucose 6-phosphate

    		Drug Intermediate Metabolic Disease
    2-Deoxy-D-glucose 6-phosphate is an intermediate of 2-deoxy-D-glucose (2-DG) . 2-Deoxy-D-glucose is incorporated into glycogen .
    2-Deoxy-D-glucose 6-phosphate
  • HY-18728
    STF-31
    10+ Cited Publications

    		 GLUT Autophagy Cancer
    STF-31 is a selective inhibitor of glucose transporter 1 (GLUT1), with an IC50 of 1 μM. STF-31 is also a NAMPT inhibitor. STF-31 inhibits glucose uptake in renal cell carcinoma (RCC) 4 cells .
    STF-31
  • HY-138842
    DDN

    		Insulin Receptor Akt ERK Metabolic Disease
    DDN is a selective insulin receptor (Insulin Receptor) activator, an insulin sensitizer, and a glucose-lowering insulin mimetic with oral bioavailability. DDN can directly bind to the receptor kinase domain and induce Akt and ERK phosphorylation, and it can also enhance insulin's effect on glucose uptake. DDN significantly reduces blood glucose levels in wild-type and diabetic ob/ob and db/db mice .
    DDN
  • HY-N2209
    Angeloylgomisin H

    		PPAR Metabolic Disease
    Angeloylgomisin H, as a major lignin extract of Schisandra rubriflora, has the potential to improve insulin-stimulated glucose uptake by activating PPAR-γ .
    Angeloylgomisin H
  • HY-D2433
    Glucose-PEG2000-Cy3

    		Fluorescent Dye Others
    Glucose-PEG2000-Cy3 is a Cy3 (HY-D0822) labeled Glucose-PEG conjugate. The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Cy3 has an emission maximum around 562-570 nm. Glucose-PEG improves drug cellular uptake and reduces endosomal degradation, and can be used in drug delivery .
    Glucose-PEG2000-Cy3
  • HY-N2486R
    Desoxyrhaponticin (Standard)

    		Fatty Acid Synthase (FASN) Apoptosis Cancer
    Desoxyrhaponticin (Standard) is the analytical standard of Desoxyrhaponticin. This product is intended for research and analytical applications. Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects .
    Desoxyrhaponticin (Standard)
  • HY-101849
    Fasentin
    4 Publications Verification

    		 GLUT TNF Receptor Apoptosis Cardiovascular Disease Cancer
    Fasentin, a potent glucose uptake inhibitor, inhibits GLUT-1/GLUT-4 transporters. Fasentin preferentially inhibits GLUT4 (IC50=68 μM) over GLUT1. Fasentin is a death receptor stimuli (FAS) sensitizer and sensitizes cells to FAS-induced cell death. Fasentin is also a tumor necrosis factor (TNF) apoptosis-inducing ligand sensitizer. Fasentin blocks glucose uptake in cancer cell lines and has anti-angiogenic activity .
    Fasentin
  • HY-163279
    Fluopipamine

    		Glycosidase Others
    Fluopipamine is an antagonist for Cellulose Synthase 1 (CESA1) with an IC50 of 0.78 μM. Fluopipamine leads a decrease in glucose uptake into cellulose and hyperaccumulation of CESAs at the PM in etiolated Arabidopsis seedlings .
    Fluopipamine
  • HY-155961
    Antidiabetic agent 2

    		Dipeptidyl Peptidase Phosphatase Amylases Glycosidase Metabolic Disease
    Antidiabetic agent 2 (Compound 56) is a glucose-uptake promoter. Antidiabetic agent 2 inhibits DPP-4, PTP-1B, α-amylase, and α-glucosidase with IC50s of 0.036, 0.042, 0.241, 0.185 μM. Antidiabetic agent 2 decreases blood glucose levels .
    Antidiabetic agent 2
  • HY-167931
    Cinnamohydrazide

    		Drug Derivative Metabolic Disease
    Cinnamohydrazide, an unsaturated carboxylic acid derivative, serves as a precursor to aspartame through enzyme-mediated amination to phenylalanine. This compound may offer potential benefits in the prevention and treatment of diabetes by facilitating insulin secretion, enhancing pancreatic β-cell function, inhibiting hepatic gluconeogenesis, promoting glucose uptake, amplifying insulin signaling pathways, delaying carbohydrate digestion and glucose absorption, and reducing protein glycation and insulin fibrillation.
    Cinnamohydrazide
  • HY-P1473
    Amylin (8-37), rat

    Amylin (8-37) (mouse, rat)

    		 Amylin Receptor Metabolic Disease
    Amylin (8-37), rat is a truncated analog of native Amylin that selectively inhibits insulin-related glucose uptake and glycogen deposition in muscle tissue. Amylin (8-37), rat is a weak amylin receptor (AMY) antagonist.
    Amylin (8-37), rat
  • HY-19843
    MK-0941

    		Glucokinase Metabolic Disease
    MK-0941 is a selective, orally active, and allosteric glucokinase activator with EC50s of 240 and 65 nM for recombinant human glucokinase in the presence of 2.5 and 10 mM glucose, respectively. MK-0941 activates hexokinase subtype IV. MK-0941 can increase insulin secretion and glucose uptake. MK-0941 can be studied in research for type 2 diabetes .
    MK-0941
  • HY-123765
    JTT-553

    		Acyltransferase Metabolic Disease
    JTT-553 is a DGAT1 inhibitor (IC50: 2.38 nM). JTT-553 reduces plasma concentrations of glucose, insulin, non-esterified fatty acids (NEFA), total cholesterol (TC), and hepatic triglycerides (TG). JTT-553 improves insulin-dependent glucose uptake and glucose intolerance in adipose tissue of DIO mice. JTT-553 reduces TNF-α mRNA levels and increases GLUT4 mRNA levels in adipose tissue of KK-Ay mice. JTT-553 improves adipose tissue insulin resistance and systemic glucose metabolism by reducing body weight. JTT-553 can be used in the study of obesity and type 2 diabetes mellitus (T2DM) .
    JTT-553
  • HY-N6258
    Kahweol

    		AMPK Apoptosis Metabolic Disease Cancer
    Kahweol is one of the consituents of the coffee from Coffea Arabica with anti-inflammatory anti-angiogenic, and anti-cancerous activities. Kahweol inhibits adipogenesis and increase glucose uptake by AMP-activated protein kinase (AMPK) activation. Kahweol induces apoptosis.
    Kahweol
  • HY-101849R
    Fasentin (Standard)

    		Reference Standards GLUT TNF Receptor Apoptosis Cardiovascular Disease Cancer
    Fasentin (Standard) is the analytical standard of Fasentin. This product is intended for research and analytical applications. Fasentin, a potent glucose uptake inhibitor, inhibits GLUT-1/GLUT-4 transporters. Fasentin preferentially inhibits GLUT4 (IC50=68 μM) over GLUT1. Fasentin is a death receptor stimuli (FAS) sensitizer and sensitizes cells to FAS-induced cell death. Fasentin is also a tumor necrosis factor (TNF) apoptosis-inducing ligand sensitizer. Fasentin blocks glucose uptake in cancer cell lines and has anti-angiogenic activity .
    Fasentin (Standard)
  • HY-130319A
    9-HEPE

    		PPAR Cardiovascular Disease Metabolic Disease
    9-HEPE, a oxidation product of Eicosapentaenoic acid, is a racemic mixture of 9(R)-HEPE and 9(S)-HEPE. 9-HEPE induces fatty acid oxidation, adipogenesis, and glucose uptake via activation of PPARs in vivo .
    9-HEPE

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: